Disease modifying therapies in heart failure: an update

There is currently limited evidence-based disease-modifying pharmacotherapy in patients with heart failure and mildly reduced/preserved ejection fraction (HFmrEF/HFpEF), forming an unmet clinical need in contemporary heart failure care. However, according to the findings from recent clinical trials with some medications such as finerenone and glucagon-like peptide-1 receptor agonist, a clinical concept of pharmacological therapy in patients with HFmrEF/HFpEF will be updated and upgraded. Based on recent evidence, we herein aim to discuss the possible roles of those medications in the HFmrEF/HFpEF therapy and propose an emerging pharmacological strategy for this population.